Plasma‐Derived Exosomal i‐tRF‐LeuCAA as Biomarker for Glioma Diagnosis and Promoter of Epithelial‐Mesenchymal Transition via TPM4 Regulation
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70356 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Hongyu Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, Beijing, China. Hauptthemen laut MEDLINE: Glioma, Epithelial-Mesenchymal Transition, Exosomes, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
This study aimed to discover plasma‐derived exosomal tsRNAs that serve as novel diagnostic biomarkers for glioma and to investigate the mechanism by which tsRNAs regulate glioma development.
Methods
Differentially expressed tsRNAs in the plasma exosomes of glioma patients were identified using small RNA array sequencing. Bioinformatics analyses were used to predict the biological function of tsRNAs. The changes in the phenotypes of glioma cells treated with a tsRNA mimic and inhibitor were detected. The diagnostic and prognostic characteristics of potential target genes and their related functions in gliomas were further analyzed. The cell and animal experiments were used to analyze the molecular mechanisms.
Results
Among the 453 differentially expressed tsRNAs identified in the plasma‐derived exosomes of glioma patients using small RNA sequencing, i‐tRF‐LeuCAA was associated with the prognosis and molecular diagnostic characteristics of glioma patients and promoted the migration, invasion, and proliferation of glioma cells and inhibited their apoptosis. In addition, TPM4 is a potential target of i‐tRF‐LeuCAA and is related to epithelial–mesenchymal transition in gliomas. Conclusions i‐tRF‐LeuCAA could be served as a non‐invasive biomarker in the diagnosis and prognosis of glioma. i‐tRF‐LeuCAA may indirectly regulate TPM4 expression and influence epithelial–mesenchymal transition, which may promote glioma progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School of Chinese PLA, Beijing, China.
- Department of Neurosurgery, Hainan Hospital of Chinese PLA General Hospital, Sanya, Hainan, China.
- Department of Neurosurgery, First Medical Center of Chinese PLA General Hospital, Beijing, China.
- School of Medicine, Nankai University, Tianjin, China.
- Laboratory of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Hongyu Liu, Wentao Hu, Ze Li, Jialin Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, H., Hu, W., Zhang, L., Li, Z., Liu, J., & Chen, L. (2025). Plasma‐Derived Exosomal i‐tRF‐LeuCAA as Biomarker for Glioma Diagnosis and Promoter of Epithelial‐Mesenchymal Transition via TPM4 Regulation. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70356
Vancouver
Liu H, Hu W, Zhang L, Li Z, Liu J, Chen L. Plasma‐Derived Exosomal i‐tRF‐LeuCAA as Biomarker for Glioma Diagnosis and Promoter of Epithelial‐Mesenchymal Transition via TPM4 Regulation. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70356
BibTeX
@article{Liu2025,
author = {Liu, Hongyu and Hu, Wentao and Zhang, Lijun and Li, Ze and Liu, Jialin and Chen, Ling},
title = {Plasma‐Derived Exosomal i‐tRF‐LeuCAA as Biomarker for Glioma Diagnosis and Promoter of Epithelial‐Mesenchymal Transition via TPM4 Regulation},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70356}
}
EUVIMED